542 related articles for article (PubMed ID: 16329111)
1. Epigenetic regulation of metallothionein-i gene expression: differential regulation of methylated and unmethylated promoters by DNA methyltransferases and methyl CpG binding proteins.
Majumder S; Kutay H; Datta J; Summers D; Jacob ST; Ghoshal K
J Cell Biochem; 2006 Apr; 97(6):1300-16. PubMed ID: 16329111
[TBL] [Abstract][Full Text] [Related]
2. Inhibitors of histone deacetylase and DNA methyltransferase synergistically activate the methylated metallothionein I promoter by activating the transcription factor MTF-1 and forming an open chromatin structure.
Ghoshal K; Datta J; Majumder S; Bai S; Dong X; Parthun M; Jacob ST
Mol Cell Biol; 2002 Dec; 22(23):8302-19. PubMed ID: 12417732
[TBL] [Abstract][Full Text] [Related]
3. Release of methyl CpG binding proteins and histone deacetylase 1 from the Estrogen receptor alpha (ER) promoter upon reactivation in ER-negative human breast cancer cells.
Sharma D; Blum J; Yang X; Beaulieu N; Macleod AR; Davidson NE
Mol Endocrinol; 2005 Jul; 19(7):1740-51. PubMed ID: 15746193
[TBL] [Abstract][Full Text] [Related]
4. Precipitous release of methyl-CpG binding protein 2 and histone deacetylase 1 from the methylated human multidrug resistance gene (MDR1) on activation.
El-Osta A; Kantharidis P; Zalcberg JR; Wolffe AP
Mol Cell Biol; 2002 Mar; 22(6):1844-57. PubMed ID: 11865062
[TBL] [Abstract][Full Text] [Related]
5. Coordinated changes in DNA methylation and histone modifications regulate silencing/derepression of luteinizing hormone receptor gene transcription.
Zhang Y; Fatima N; Dufau ML
Mol Cell Biol; 2005 Sep; 25(18):7929-39. PubMed ID: 16135786
[TBL] [Abstract][Full Text] [Related]
6. Promoter- and cell-specific epigenetic regulation of CD44, Cyclin D2, GLIPR1 and PTEN by methyl-CpG binding proteins and histone modifications.
Müller I; Wischnewski F; Pantel K; Schwarzenbach H
BMC Cancer; 2010 Jun; 10():297. PubMed ID: 20565761
[TBL] [Abstract][Full Text] [Related]
7. Role of DNA methyltransferases in regulation of human ribosomal RNA gene transcription.
Majumder S; Ghoshal K; Datta J; Smith DS; Bai S; Jacob ST
J Biol Chem; 2006 Aug; 281(31):22062-22072a. PubMed ID: 16735507
[TBL] [Abstract][Full Text] [Related]
8. Promoter methylation and silencing of the tissue factor pathway inhibitor-2 (TFPI-2), a gene encoding an inhibitor of matrix metalloproteinases in human glioma cells.
Konduri SD; Srivenugopal KS; Yanamandra N; Dinh DH; Olivero WC; Gujrati M; Foster DC; Kisiel W; Ali-Osman F; Kondraganti S; Lakka SS; Rao JS
Oncogene; 2003 Jul; 22(29):4509-16. PubMed ID: 12881707
[TBL] [Abstract][Full Text] [Related]
9. Methylation-mediated proviral silencing is associated with MeCP2 recruitment and localized histone H3 deacetylation.
Lorincz MC; Schübeler D; Groudine M
Mol Cell Biol; 2001 Dec; 21(23):7913-22. PubMed ID: 11689684
[TBL] [Abstract][Full Text] [Related]
10. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex.
Nan X; Ng HH; Johnson CA; Laherty CD; Turner BM; Eisenman RN; Bird A
Nature; 1998 May; 393(6683):386-9. PubMed ID: 9620804
[TBL] [Abstract][Full Text] [Related]
11. Methyl-CpG binding domain proteins and their involvement in the regulation of the MAGE-A1, MAGE-A2, MAGE-A3, and MAGE-A12 gene promoters.
Wischnewski F; Friese O; Pantel K; Schwarzenbach H
Mol Cancer Res; 2007 Jul; 5(7):749-59. PubMed ID: 17634428
[TBL] [Abstract][Full Text] [Related]
12. Regulation of transcription and chromatin by methyl-CpG binding protein MBD1.
Nakao M; Matsui S; Yamamoto S; Okumura K; Shirakawa M; Fujita N
Brain Dev; 2001 Dec; 23 Suppl 1():S174-6. PubMed ID: 11738867
[TBL] [Abstract][Full Text] [Related]
13. hMLH1 promoter methylation and silencing in primary endometrial cancers are associated with specific alterations in MBDs occupancy and histone modifications.
Xiong Y; Dowdy SC; Eberhardt NL; Podratz KC; Jiang SW
Gynecol Oncol; 2006 Oct; 103(1):321-8. PubMed ID: 16701802
[TBL] [Abstract][Full Text] [Related]
14. Biochemical analysis of histone deacetylase-independent transcriptional repression by MeCP2.
Theisen JW; Gucwa JS; Yusufzai T; Khuong MT; Kadonaga JT
J Biol Chem; 2013 Mar; 288(10):7096-104. PubMed ID: 23349465
[TBL] [Abstract][Full Text] [Related]
15. The methyl-CpG-binding protein MeCP2 links DNA methylation to histone methylation.
Fuks F; Hurd PJ; Wolf D; Nan X; Bird AP; Kouzarides T
J Biol Chem; 2003 Feb; 278(6):4035-40. PubMed ID: 12427740
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase inhibitor LBH589 reactivates silenced estrogen receptor alpha (ER) gene expression without loss of DNA hypermethylation.
Zhou Q; Atadja P; Davidson NE
Cancer Biol Ther; 2007 Jan; 6(1):64-9. PubMed ID: 17172825
[TBL] [Abstract][Full Text] [Related]
17. Altered chromatin structure associated with methylation-induced gene silencing in cancer cells: correlation of accessibility, methylation, MeCP2 binding and acetylation.
Nguyen CT; Gonzales FA; Jones PA
Nucleic Acids Res; 2001 Nov; 29(22):4598-606. PubMed ID: 11713309
[TBL] [Abstract][Full Text] [Related]
18. Heterogeneity in the modification and involvement of chromatin components of the CpG island of the silenced human CDH1 gene in cancer cells.
Koizume S; Tachibana K; Sekiya T; Hirohashi S; Shiraishi M
Nucleic Acids Res; 2002 Nov; 30(21):4770-80. PubMed ID: 12409468
[TBL] [Abstract][Full Text] [Related]
19. Methyl-CpG binding domain 1 (MBD1) interacts with the Suv39h1-HP1 heterochromatic complex for DNA methylation-based transcriptional repression.
Fujita N; Watanabe S; Ichimura T; Tsuruzoe S; Shinkai Y; Tachibana M; Chiba T; Nakao M
J Biol Chem; 2003 Jun; 278(26):24132-8. PubMed ID: 12711603
[TBL] [Abstract][Full Text] [Related]
20. MBD3L2 interacts with MBD3 and components of the NuRD complex and can oppose MBD2-MeCP1-mediated methylation silencing.
Jin SG; Jiang CL; Rauch T; Li H; Pfeifer GP
J Biol Chem; 2005 Apr; 280(13):12700-9. PubMed ID: 15701600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
